Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs. 2006;66:111–31.

Article  CAS  PubMed  Google Scholar 

Kwiatkowski J, Kuliszkiewicz-Janus M, Rymer W, Jaźwiec B, Małecki R. Treatment of essential thrombocythemia with anagrelide is associated with an increased risk of worsened kidney function. Pharmacology. 2021;106:316–22.

Article  CAS  PubMed  Google Scholar 

Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, Herrmann S, Tefferi A, D’Agati VD, Nasr SH. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011;80:753–9.

Article  PubMed  Google Scholar 

Krečak I, Holik H, Martina MP, Zekanović I, Coha B, Gverić-Krečak V. Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera. Int J Hematol. 2020;112:377–84.

Article  PubMed  Google Scholar 

Rodwell GEJ, Troxell ML, Lafayette RA. Renal tubular injury associated with anagrelide use. Nephrol Dial Transplant. 2005;20:988–90.

Article  PubMed  Google Scholar 

Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica. 2004;89:520–7.

PubMed  Google Scholar 

Moreno JCA, Bahmad HF, Febres-Aldana CA, Pirela A, Azuero A, Salami A, Poppiti R. Post-mortem assessment of vimentin expression as a biomarker for renal tubular regeneration following acute kidney injury. J Pathol Transl Med. 2021;55:369–79.

Article  PubMed  PubMed Central  Google Scholar 

Au WY, Chan KW, Lui SL, Lam CCK, Kwong YL. Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders. Am J Kidney Dis. 1999;34:889–93.

Article  CAS  PubMed  Google Scholar 

Tamura K, Haruhara K, Azushima K, Iwamoto T, Wakui H. Possible interesting link between Janus kinase 2 mutation and renovascular hypertension. J Clin Hypertens. 2018;20:805–6.

Article  Google Scholar 

Rastaldi MP, Ferrario F, Giardino L, Dell’antonio G, Grillo C, Grillo P, Strutz F, Müller GA, Colasanti G, D’Amico G. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int. 2002;62:137–46.

Article  PubMed  Google Scholar 

Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Prim. 2021;7:52.

Article  PubMed  Google Scholar 

Palmblad J, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Mauritzson N, Westin J, Samuelsson J, Birgegård G. TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. Int J Med Sci. 2008;5:87–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lahiri P, Chaudhuri U, Chattopadhyay A, Dasgupta AK. Platelet aggregation profile as a marker of hydroxyurea bioavailability through nitric oxide generation in chronic myelogenous leukemia. Leuk Lymphoma. 2006;47:741–6.

Article  CAS  PubMed  Google Scholar